文献速递药物不良反应与药物警戒特殊人群用药肝肾功能剂量调整

醋酸艾司利卡西平辅助治疗成人难治性局灶性癫痫的安全性:从临床研究到6年上市后经验

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.
PubMed 文献 · Drug Saf · 2017-01-01

该研究汇总四项III期随机双盲安慰剂对照试验及特殊人群研究,并分析2009至2015年上市后安全性数据库。结果显示治疗期不良事件呈剂量依赖性,头晕、嗜睡、头痛和恶心最常见;上市后低钠血症报告率10.2%,为最常见药物不良反应,超过半数发生于日剂量1200 mg时。6年上市后监测的安全性特征与关键临床试验相似。

要点

  • 头晕、嗜睡、头痛和恶心是最常见治疗期不良事件,多数为轻至中度。
  • 治疗期不良事件及导致停药的不良事件发生率呈剂量依赖性。
  • 上市后低钠血症报告率10.2%,超半数病例发生于日剂量1200 mg。

核心结论

  • 经过6年上市后监测,醋酸艾司利卡西平的安全性特征与关键临床研究中所观察到的相似。

研究设计与样本

  • 采用四项III期双盲随机安慰剂对照研究(BIA-2093-301、-302、-303、-304)的事后汇总安全性分析,评估醋酸艾司利卡西平作为成人辅助治疗的安全性。
  • 同时纳入特殊人群研究的安全性数据:年龄≥65岁伴部分性发作患者(BIA-2093-401)、中度肝功能损害受试者(BIA-2093-111)和肾功能损害受试者(BIA-2093-112)。
  • 分析2009年10月1日至2015年10月21日期间醋酸艾司利卡西平全球安全性数据库中的所有上市后监测病例。

主要发现

  • 四项III期研究汇总分析显示,治疗期不良事件、导致停药的治疗期不良事件及药物不良反应的发生率呈剂量依赖性。
  • 头晕、嗜睡、头痛和恶心是最常见的治疗期不良事件(≥10%患者),大多数为轻至中度强度。
  • 严重不良事件未观察到剂量依赖性趋势,个体严重不良事件报告率低于1%患者。
  • III期研究中低钠血症被归类为可能相关的治疗期不良事件(1.2%);6年上市后监测中低钠血症为最常报告的药物不良反应(10.2%),其中超过一半病例发生于醋酸艾司利卡西平日剂量1200 mg时。
  • 上市后监测中其他报告的药物不良反应包括癫痫发作(5.8%)、头晕(4.1%)、皮疹(2.6%)和疲劳(2.1%)。

关键数值与推荐

  • III期研究中低钠血症作为可能相关治疗期不良事件的发生率为1.2%。
  • 上市后监测中低钠血症报告率为10.2%,超过半数病例发生于日剂量1200 mg时。
  • 上市后监测中其他药物不良反应报告率:癫痫发作5.8%、头晕4.1%、皮疹2.6%、疲劳2.1%。
  • 严重不良事件个体报告率低于1%患者,未观察到剂量依赖性趋势。
  • 肾功能损害、肝功能损害(I期研究)及老年患者(III期研究)中醋酸艾司利卡西平的安全性特征未引起特殊关注。

临床怎么用

  • 临床使用醋酸艾司利卡西平时应关注头晕、嗜睡、头痛和恶心等常见不良事件,多数为轻至中度。
  • 应警惕低钠血症风险,尤其当日剂量为1200 mg时,上市后监测显示超过半数低钠血症病例发生于该剂量。
  • 对于肾功能损害、中度肝功能损害及年龄≥65岁患者,现有安全性数据未提示特殊安全性问题。

局限性

  • III期安全性数据来自事后汇总分析,特殊人群数据来自单独的I期或III期研究。
  • 上市后监测数据为自发报告,可能存在报告偏倚和低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Eslicarbazepine acetate was first approved in the European Union in 2009 as adjunctive therapy in adults with partial-onset seizures with or without secondary generalization. OBJECTIVE: The objective of this study was to review the safety profile of eslicarbazepine acetate analyzing the data from several clinical studies to 6 years of post-marketing surveillance. METHODS: We used a post-hoc pooled safety analysis of four phase III, double-blind, randomized, placebo-controlled studies (BIA-2093-301, -302, -303, -304) of eslicarbazepine acetate as add-on therapy in adults. Safety data of eslicarbazepine acetate in special populations of patients aged ≥65 years with partial-onset seizures (BIA-2093-401) and subjects with moderate hepatic impairment (BIA-2093-111) and renal impairment (BIA-2093-112) are also considered. The incidences of treatment-emergent adverse events, treatment-emergent adverse events leading to discontinuation, and serious adverse events were analyzed. The global safety database of eslicarbazepine acetate was analyzed for all cases from post-marketing surveillance from 1 October, 2009 to 21 October, 2015. RESULTS: From a pooled analysis of four phase III studies, it was concluded that the incidence of treatment-emergent adverse events, treatment-emergent adverse events leading to discontinuation, and adverse drug reactions were dose dependent. Dizziness, somnolence, headache, and nausea were the most common treatment-emergent adverse events (≥10% of patients) and the majority were of mild-to-moderate intensity. No dose-dependent trend was observed for serious adverse events and individual serious adverse events were reported in less than 1% of patients. Hyponatremia was classified as a possibly related treatment-emergent adverse event in phase III studies (1.2%); however, after 6 years of post-marketing surveillance it represents the most frequently (10.2%) reported adverse drug reaction, with more than half of these cases occurring with eslicarbazepine acetate at daily doses of 1200 mg. Other adverse drug reactions reported in post-marketing surveillance are seizure (5.8%), dizziness (4.1%), rash (2.6%), and fatigue (2.1%). The safety profile of eslicarbazepine acetate in renal and hepatic impairment subjects (phase I studies) and in elderly patients (phase III study) did not raise any specific concern. CONCLUSION: After 6 years of post-marketing surveillance, eslicarbazepine acetate maintains a similar safety profile to that observed in pivotal clinical studies.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Gama H, Vieira M, Costa R, et al. Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience. Drug Saf. 2017. PMID: 28752473. doi:10.1007/s40264-017-0576-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。